Introduction Adverse drug events (ADEs) may represent an important item of expenditure for healthcare systems and their prevention could be associated with a relevant cost saving. Objective The objective of this study was to simulate the annual economic burden for ADEs in Tuscany (Italy) and the potential cost savings related to avoidable ADEs. Methods A systematic review was performed, according to the Preferred Reporting Items for Systematic review and MetaAnalysis (PRISMA) and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statements, on observational studies published from 2006 to 2016 in MEDLINE and EMBASE, focusing on direct costs of ADEs in the inpatient setting from high-income countries. The mean probability of preventable ADEs was estimated over the included studies. The mean ADE cost was calculated by means of Monte Carlo simulation. We then extrapolated the spontaneous reports of ADEs in Tuscany, Italy in 2016 from the Italian National Pharmacovigilance Network (Rete Nazionale di Farmacovigilanza), and we assumed the same costs and preventability probability for these as obtained in the systematic review. Finally, we simulated the possible costs of ADEs and preventable ADEs in Tuscany. Three sensitivity analyses were also performed to test the robustness of the results. Results Of 11,936 articles initially selected, 12 observational studies were included. The estimated mean [± standard deviation (SD)] ADE cost was €2471.46 (± €1214.13). The mean (± SD) probability of preventable ADEs was 45% (± 21). The Tuscan expenditure for ADEs was €3,406,280.63 per million inhabitants (95% confidence interval (CI) 1,732,910.44-5,079,664.61) and the potential cost saving was €1, 532,760.25 per million inhabitants (95% CI 779,285,750.60). Sensitivity analyses confirmed the robustness of the results. Conclusions The present simulation showed that ADEs could have a relevant economic impact on the Tuscan healthcare system. In this setting, the prevention of ADEs would result in important cost savings. These results could be likely extended to other healthcare systems.
Introduction
Pharmacovigilance is aimed at detecting rare and uncommon serious adverse drug reactions (ADRs) [1] [2] [3] , identifying major drug-related safety problems and issuing riskminimisation strategies to prevent drug-related harm [4] . ADRs can occur in several settings, but those occurring in inpatients are better documented and result more frequently in significant health and economic costs than those in outpatients [2, 5] . It has been estimated that 5% of hospital admissions are related to ADRs [6, 7] , and about 22% of hospitalised patients will develop an ADR [7] . The overall rates of serious and fatal ADRs in the hospital setting are 6.7% (95% confidence interval (CI) 5.2-8.2) and 0.32% (95% CI 0.23-0.41), respectively [8] .
Module I of the "Guideline on Good Pharmacovigilance Practices" states that a good-quality drug safety surveillance system could lead to prevention of ADRs [9] . Since the recall, repair or rework of faults from ADRs and their management are costly and time consuming [7, 10, 11] , the prevention of ADRs should allow ADR-related economic charges to be saved. These costs can be variable across different settings (e.g. inpatients vs. outpatients) and healthcare systems (e.g. developed vs. developing countries). Several observational studies have attempted an evaluation of costs of ADRs or adverse drug events (ADEs) (which include ADRs by definition [12, 13] ), but their results are extremely variable and difficult to compare. In the present study, we tried to apply health economics to pharmacovigilance, with the aim of simulating the possible annual expenditure for ADEs in Tuscany (Italy) and the potential savings achievable if all the preventable ADEs were actually prevented.
Methods
We conducted this study in two main steps. In the first step, we extrapolated the mean cost of a single ADE and the preventability probability from the medical literature. In the second step, we used these data to simulate the economic burden of ADEs in Tuscany and the potential cost savings associated with their prevention. A flowchart of the study is given in Fig. 1 .
Data Sources
Data on the ADE mean cost and ADE preventability probability were obtained from a systematic review of published articles, in accordance with the Preferred Reporting Items for Systematic review and Meta-Analysis (PRISMA) [14] and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) statements [15] . Studies were selected using MEDLINE and EMBASE. The simulation analysis to estimate the economic burden of ADEs in Tuscany was conducted on data regarding ADEs reported spontaneously to the Italian National Pharmacovigilance Network [Rete Nazionale di Farmacovigilanza (RNF)]. This network is the basis of the current Italian pharmacovigilance system and contains information about patients experiencing ADEs (i.e. demographic information), ADE characteristics (e.g. seriousness, severity, time to onset, etc.), drug treatments (e.g. dose, route of administration, dates of therapy, etc.) and report source (i.e. geographical origin of the report, reporter qualification).
Search Strategy
We conducted a systematic search of studies published in the MEDLINE and EMBASE databases. Keywords are provided in detail in Electronic Supplementary Material (ESM) file 1. The research was restricted to observational studies published in the period from 1 January 2006 to 31 December 2016. The reference lists of selected studies were also checked for additional relevant articles. Duplicates were removed firstly using the Mendeley auto-deduplication tool [16] and then by manual assessment. In particular, references were ordered alphabetically according to the first author's name and thereafter according to their titles. Two different reviewers (IC, MTG) examined the retrieved papers to check for duplicates. The relevance of studies was evaluated by assessing the title and abstract. If the study eligibility remained unclear, the full text was read. Any disagreement was resolved by discussion with a senior reviewer (MT).
Study Inclusion and Exclusion Criteria
Since the methodology used to calculate the costs of ADEs is extremely variable across studies, we built up the inclusion criteria based on features of homogeneity to achieve maximum comparability. Therefore, studies had to fulfil the following characteristics to be eligible: full-text studies published in English language only; performed in high-income countries [17] ; and considering direct costs of ADEs in inpatient settings only. In addition, we included studies if they reported the mean cost of a single ADE; their results allowed the extrapolation of the mean cost of a single ADE; or they reported the mean cost for one patient with a single ADE (or this information could be extrapolated). In the last case, the average number of events per single patient had to be one or close to one [18] . Studies published as an abstract only were excluded, as were studies focused on specific ADEs for drugs or drug classes (e.g. studies on oncologic patients only, intensive care only, addressing antidiabetic drugs or opioids, or just on intravenous drugs) or those performed on outpatients only. We also did not include studies that reported costs as median values only, and those with a small sample of ADEs or patients with one ADE (n < 100).
Data Extraction
For each selected study the following information was collected: country; study design; observation period; study duration; number of involved clinical centres; mean age of the population; definition of ADEs; number of patients with one ADE; number of ADEs; mean cost per single ADE with standard deviation (SD), 95% CI or standard error (SE) when available (alternatively, the total costs of ADEs or patients with one ADE); currency used to indicate the costs; and features of direct costs. When available, the definition of preventable ADEs, probability of ADE preventability (percentage of preventable ADEs over the total number of ADEs) and methods used for preventability assessment were extracted.
Study Quality Assessment
The methodological quality of the included studies was assessed by the Newcastle-Ottawa Scale for the case-control and cohort studies [19] , as well as by a modified version of the Newcastle-Ottawa Cohort Scale for cross-sectional studies [20] . The Newcastle-Ottawa Scale is a 9-point scale for cohort or case-control studies, which estimates the following risk biases: selection process (maximum 4 points); comparability (maximum 2 points); and identification of the exposure for case and control groups or the outcomes for cohorts (maximum 3 points). Studies were classified as at low or high risk of bias when the total score was < 3 and ≥ 3 points, respectively. The modified version of the Newcastle-Ottawa Quality Assessment Scale for cross-sectional studies [20] is a 10-point scale in which the assessments of comparability, exposure and outcome change according to the different study designs. This scale also includes evaluation of the quality of the statistical method. Two reviewers (IC, SF) independently evaluated the quality of the studies and a third reviewer (MT) resolved disagreements.
Data Analysis

Data Analysis: Actualisation of Costs
Costs were reported using the currency provided in the original articles. If the year of estimation of the currency value was not reported, we used the study period of observation as the index year. In order to make a comparison of costs and related SD, 95% CI or SE, an actualisation process was performed in two steps as suggested by Batel Marques et al. [4] . In particular, costs were first updated to December 2016 according to the following calculation [(Consumer Price Index [21] in 2016/Consumer Price Index in the year of analysis) × mean cost in the study]. These costs were then converted into euros using conversion values at 30 December 2016 [22] .
Data Analysis: Simulated Mean Cost of a Single Adverse Drug Event (ADE)
Once the sampling distribution of the means was estimated for all of the included studies, sample averages were randomly extracted through the Monte Carlo simulation. This simulation is a stochastic model, which selects values from the distributions simultaneously and randomly, and then lists the outcome for a large number of hypothetical samples [23, 24] . Each scenario was simulated twice-1000 and 10,000 times, respectively-and weighted for the Newcastle-Ottawa Scale score. For example, if the score was 6, the study had 6000 values in the first simulation and 60,000 in the second one. Consequently, studies with a high score had a greater weight in the final distribution. The mean of the pooled distribution was considered as the point estimation, and the lower and upper limits of its 95% CI were obtained as the 2.5 and 97.5 percentiles. According to the central limit theorem the average values were sampled directly from a normal distribution. Since only a few studies reported the SD or 95% CI [25] [26] [27] [28] [29] [30] [31] , in order to estimate the distribution of the average cost for all the included studies variability was extrapolated for missing studies by assuming that variability might depend on features of direct costs. Consequently, studies were clustered according to the cost items considered for the analysis, e.g. Diagnosis-Related Group or emergency department visit and hospital stay. At least one study with a symmetric 95% CI belonged to each group, and this allowed estimation of the variability. The SD was derived by also assuming a Normal distribution for studies with missing data and by making their SD proportional to the mean value of a study belonging to the same group with a known variability. In the case of several studies with a reference variability, we considered the study with the closer sample size. The coefficient of variation was hypothesised to be equal. The variability of each study was calculated using the CI or SD. If the CI was not symmetrical, we considered the bigger margin of error. Since costs cannot be negative, negative values in the distributions were dropped and a further analysis, assuming a truncated Normal distribution, was performed to test the effects of dropping these values.
Probability of Preventable ADEs
The articles selected for evaluation of the mean ADE cost were also reviewed for the assessment of preventability probability. The mean (with SD) percentage of preventable ADEs was calculated from the preventability percentages given in the selected studies.
ADEs Reported in Tuscany
To simulate the economic burden of ADEs in Tuscan hospital settings, we selected reports from the RNF database using the following criteria: reporting date from 1 January 2016 to 31 December 2016 in Tuscany; and hospital and specialist physicians as reporting source. Literature reports were excluded from the dataset. The number of Tuscan inhabitants provided by the National Institute of Statistics [Istituto Nazionale di Statistica (ISTAT)] at 31 December 2016 was used to normalise the total estimated costs of ADEs per million inhabitants.
Simulation of Potential Costs for ADEs and Cost Savings in Tuscany
Assuming that the costs of ADEs in Tuscany are close to those calculated by means of our systematic review and Monte Carlo simulation, we considered the mean cost resulting from simulation analysis for each Tuscan ADE, extracted as described in Sect. 2.8, to calculate the overall costs of ADEs in Tuscany. Potential cost savings were estimated as the costs of ADEs that were expected to be prevented in Tuscany based on the preventability probability estimated in the systematic review, assuming that preventability probability in Tuscany was close to that of the systematic review and that all preventable ADEs could be avoided. Results were normalised per million inhabitants.
Sensitivity Analyses
Since costs are variable measures in nature, probabilistic sensitivity analysis in economic modelling allows quantification of the level of confidence in the results of the research, related to the uncertainty in the model input values. This tests the uncertainty of variables on values as distributions [23] . In order to check for the robustness of our analysis, we performed four sensitivity analyses [32] . The first sensitivity analysis was performed by means of Monte Carlo simulation, assuming the best-and the worst-case scenario when variability was the smallest and the largest, respectively. Variability was assessed adopting the lowest SD for the best situation (i.e. Perrone et al. [28] ) and the highest SD for the worst-case scenario (i.e. Meier et al. [27] ). In order to evaluate the stability of the model for variability, studies belonging to the best situation were excluded, according to the rank of estimated SD values, while studies associated with the worst-case scenario were eliminated by a decreasing method. The articles with missing SDs were made proportional to the mean value reported in the studies with variability, without taking into account the cost items. In order to test the impact of differences in purchasing power between countries on our results, a second sensitivity analysis was performed.
In this sensitivity analysis, the purchasing power parities (PPPs) related to health goods and services were used to equalise the purchasing power of different currencies. The 2014 Eurostat-Organisation for Economic Co-operation and Development (OECD) PPPs were extracted, since PPPs are updated every 3 years on the OECD website. Consequently, the mean cost of a single ADE was firstly updated to 2014, then adjusted for PPPs, and finally updated to 2016. However, since PPP is calculated including several cost items and services provided by healthcare systems across countries, and since the cost of ADEs in the selected studies was calculated on the basis of heterogeneous items and services, we decided to perform a third sensitivity analysis using the Big Mac index as a proxy of purchasing power [33] . Since the assessment of preventability probability may vary across studies, a fourth sensitivity analysis was performed taking into consideration only those studies where this percentage was assessed by means of the most common standardised methodology employed in the selected studies, namely the Schumock and Thornton approach [34] .
Statistical Analysis
All descriptive statistical analyses were performed using Microsoft Office Excel ® , 2016 (Microsoft Corporation, Redmond, WA, USA) and Monte Carlo simulations were conducted using STATA ® Statistical Software: Release 13 (StataCorp LP, College Station, TX, USA) and R version 3.4.2 (R Foundation for Statistical Computing, Vienna, Austria).
Results
Search Results
According to our search strategy, 11,936 articles were selected initially. After applying the inclusion and exclusion criteria, 12 observational studies were included in the analysis [18, [25] [26] [27] [28] [29] [30] [31] [35] [36] [37] [38] . The study selection flowchart is shown in Fig. 2. 
Characteristics of the Included Studies
Of the 12 included observational studies, three were performed in the USA [18, 36, 37] , three in Germany [27, 29, 30] , two in the Netherlands [26, 35] , one in Spain [38] , one in Canada [31] , one in the UK [25] and one in Italy [28] . Most of these studies (n = 8) had a cross-sectional study design [25-29, 31, 35, 38] , two were cohort studies [18, 37] and two were case-control studies [30, 36] . Two studies evaluated data from a single hospital centre [25, 27] , seven studies were performed on data recorded in several hospital centres [18, 26, 28-30, 35, 36] , while three studies screened records from national [37, 38] and provincial [31] healthcare databases. With regard to the study population, five studies were conducted on adults [18, [27] [28] [29] 35] , three on all ages [26, 30, 38] , two on children [25, 36] and one on elderly subjects [31] , while only one study did not report this information [37] . ADEs occurred during hospitalisation were evaluated in four studies [18, 26, 30, 36] , while ADEs causing hospitalisation were assessed in the remaining studies [25, 27-31, 35, 37, 38] . ADEs were identified by the International Classification of Diseases (ICD) 9th revision in 59% of cases (n = 7) [18, 26, 27, [35] [36] [37] [38] and by the 10th revision of the ICD in 25% of studies (n = 3) [29] [30] [31] , while in 16% the information was not available (n = 2) [25, 28] . Patient medical records were the most used data source [18, 26-30, 35, 36] , followed by databases [31, 37, 38] and hospital information systems [25] (Table 1) . 
Quality Assessment of Studies
According to the quality assessment, all of the included studies reached the minimum score (i.e. 4) and were classified as having a low risk of bias [18, [25] [26] [27] [28] [29] [30] [31] [35] [36] [37] [38] (see ESM  Tables 1a-c) . Regarding the selection approach, two studies referred to an independent validated source such as medical/ hospital records [30, 36] , two evaluated the representativeness of individuals with ADEs among inpatients [18, 37] and eight focused on the representativeness of the average in the target population [25-29, 31, 35, 38] . The two case-control studies defined cases, i.e. patients with ADEs, over an observational period lasting 1 year in a group of hospitals and they used the same source for case and control group selection [30, 36] . In the two cohort studies, the non-exposed group were from the same source as the exposed group and these were selected via secure items (e.g. medical records) [18, 37] . Exposure to ADEs was ascertained by a defined tool (e.g. ICD codes) in ten studies [18, 26, 27, [29] [30] [31] [35] [36] [37] [38] . Seven of the 12 studies provided comparability on inpatients in the different outcome groups [26, 31, 35, 38] , between cases and controls [30, 36] , or among the study cohort on the basis of the study design [18] .
The outcome was assessed by secure records (e.g. medical records) [18] or by record linkage through ICD codes [37] in the two cohort studies, with a complete and adequate follow-up period [18, 37] . However, among the cross-sectional studies, two evaluated the outcome through the clinical judgement of a team [28, 29] and the others by hospital records in linked systems [25-27, 31, 35, 38] ; each of these studies adopted statistical tests for the analysis [25-29, 31, 35, 38] . Exposure was allocated by secure items (e.g. medical records), and this method was ascertained for both cases and controls in the two studies with a case-control design [30, 36] . None of these studies reported a non-response rate for the groups.
Cost Analysis in the Included Studies
For the cost evaluation, 50% of the included studies based their analysis on Diagnosis-Related Groups [18, 27-29, 36, 38] , while the remaining studies reported their cost items heterogeneously [25, 26, 30, 31, 35, 37] . Notably, seven studies also included the intensive care unit charges [25-27, 29, 30, 35, 36] . The mean cost was reported in 75% of studies (n = 9) [18, 25-30, 35, 36] , while we calculated it in 25% (n = 3) it was calculated [31, 37, 38] . The index year for the currency value was stated in seven studies [18, 25, 26, 31, 35, 36, 38] ; in the remaining studies [27] [28] [29] [30] 37] , the observation period was used as the index year for the currency value. The crude mean cost for a single ADE ranged from US$2620 to US$5373 in the US studies, and from €970 to €5461 in the European studies ( Table 2) .
The actualised mean (± SD) cost for a single ADE in inpatients ranged from €172.75 (± 452) to €4162.44 in the included studies. Notably, the mean ADE cost in the North American studies ranged from €1694.43 to €4162.44, while the mean cost value in Europe ranged from €172.75 to €3127.69 (Table 2) .
Mean ADE Cost Simulation and Sensitivity Analyses
According to direct cost features, three different groups were identified for variability estimation among the included studies. Figure 1 ). Similar results were obtained by truncated Normal distributions (see ESM Table 2 ). Since no considerable differences between 1000-and 10,000-weighted sample sets were obtained in the previous analysis, only the 1000-sample set was selected for the first sensitivity analysis. When variability was assessed independently by the features of costs in all included studies, the mean cost for single ADE was €2454.44 (95% CI 1164.24-3744.64) in the worst-case scenario based on the 1000-sample set weighted for the Newcastle-Ottawa Scale score. However, the simulation generated an asymmetric negative skewness when the best situation was evaluated. The skewness became positive after withdrawal of Perrone et al. [28] from the model. Consequently, taking Rottenkolber et al. [30] (analysis 1) as the lower SD, the average cost from the simulation based on the 1000-weighted sample set for the best-and the worstcase scenario was €2566.66 (95% CI 1686.18-3447.15) and €2571.34 (95% CI 1356.41-3786.27), respectively. Similar costs were generated after negative values were dropped (€2471.46; 95% CI 1257.33-3685.59) ( Table 3) and following simulation of the best-case (€2570.40; 95% CI 1695.81-3445.00) and worst-case scenario (€2593.03; 95% CI 1405.43-3780.64) (see ESM Table 3 and Figure 2) . When the mean costs were adjusted for PPPs in the second sensitivity analysis (see ESM Table 4 ), the mean ADE cost was €2960.79 (95% CI 1138.67-€4782.91) (see ESM Table 3 and Figure 3 ). Finally, in the third sensitivity analysis, when the Big Mac index was used as a proxy of PPP (see ESM 
Subanalysis: Preventability
Of the 12 studies, only seven evaluated preventability [18, [25] [26] [27] [28] [29] 35] . In four cases the Schumock and Thornton criteria [34] were adopted for preventability assessment [27] [28] [29] 35] , while in two [18, 26] and one studies [25] clinical judgement and Hallas criteria [39] were used, respectively. The estimated probability of preventable ADEs ranged from 20.1 to 80%; details are provided in ESM Table 6 . The mean (± SD) probability of preventable ADEs estimated from the included studies [18, [25] [26] [27] [28] [29] 35] was 45% (± 21). When considering the fourth sensitivity analysis, in which preventability was calculated only from the selected studies using Schumock and Thornton criteria [27] [28] [29] 35] , the mean (± SD) preventability probability was 43% (± 17) (see ESM Table 6 ).
Potential Preventable ADEs in Tuscany
A total of 6182 ADE reports were recorded in the RNF database in 2016 for Tuscany at 17 January 2017. The population recorded at 31 December 2016 was 3,742,437, yielding 1652 ADE cases per million inhabitants. Overall, 5158 (83.44%) of Tuscan ADE cases were reported from the hospital setting, corresponding to 1378 reports per million inhabitants. Therefore, in Tuscany in 2016 we could expect that 2321 ADEs reported from a hospital source could have been prevented (620 preventable ADE cases per million inhabitants), or 2218 ADEs according to Schumock and Thornton criteria [34] (593 preventable ADE cases per million inhabitants) ( Table 4 ).
Potential Costs of ADE Cases in Tuscany:
Simulation and Sensitivity Analyses
According to the estimations given in Sect. (Table 6 ).
Discussion
To the best of our knowledge, this systematic review is the first attempt to estimate the mean ADE direct cost in a hospital setting by means of Monte Carlo simulation using observational data and weighting for the risk of bias. We pooled the ADE cost estimates and combined them with data on the frequency of ADEs from Tuscany to estimate the potential direct costs of ADEs in Tuscany. The methodology used most frequently in the included studies was a cross-sectional design (67%; n = 8) [25-30, 35, 38] with a moderate quality assessment (6/10 average Newcastle-Ottawa Adapted Scale score), followed by cohort (16.5%; n = 2) and case-control studies (16.5%; n = 2) with a high-quality assessment (7/8 average Newcastle-Ottawa Scale score). In accordance with the literature [40] , in our study the simulated costs of hypothetical ADEs had a positively skewed distribution, with the majority of patients consuming small amounts of resources and a minority accumulating considerable expenditure. The present study suggests that the avoidance of preventable ADEs could have resulted in a potential cost saving of €5,736,258.66 in 2016 in an Italian region of about 4 million inhabitants. This result should stimulate healthcare systems to consider investing in pharmacovigilance to improve their economic performance. Of course, the cost effectiveness of proactive pharmacovigilance projects should be considered before any investments are made and, when opportune, these should possibly be supported with dedicated funding.
It is important to test several approaches to improve the number of prevented ADEs. Improved preventability of ADEs and related cost avoidance could be achieved by continuous education of healthcare professionals on pharmacovigilance [41, 42] ; pharmacological support by a specialised team [43] ; computerised healthcare systems, including automated dispensing machines, medication alerting systems, bar coding and computerised medical records [44, 45] ; and implementation of standardised procedures [46] . Notably, subsequent synergic actions among clinical pharmacological support, computerised hospital systems and clinical decision-making [47] , along with continuous optimisation of the synergic network for up to 2 years [45] , appears to be particularly efficient. Indeed, a high-quality healthcare system relies on a suitable sociotechnical basis in which technologies, healthcare professionals, workflow processes, the healthcare organisation setting and regulatory environments interact successfully [42] . Gallagher et al. [43] showed that even pharmacological support by a specialised team only could generate a cost avoidance of €708,221, corresponding to about 12% of the estimated preventable costs of ADEs in the Tuscan healthcare system.
Our study has several strengths. First, we attempted to estimate the mean ADE cost from studies published in the medical literature by making them as comparable as possible by means of restrictive inclusion criteria (e.g. the inclusion of studies performed only in developed countries and in a hospital setting), and subsequently by updating and converting costs into a single currency (€). Second, our results were almost constant across sensitivity analyses. For instance, the evaluation of the best-and worst-case scenario and the adjustment for PPPs allowed us to control the possible heterogeneity among the included studies due to the methodological differences in cost assessment and the variable nature of costs across the healthcare systems. Notably, the PPPs for health goods and services were used to make costs of ADEs comparable across countries for the first time.
Some limitations related to both the first (cost extrapolation) and second (extraction of Tuscan ADEs) step of the study should be pointed out as well.
First, with regard to the cost extrapolation, purchasing power across countries must be taken into consideration. Accordingly, in our analysis we adjusted costs by using PPPs for health goods and services and the Big Mac index. Notably, these approaches provided similar results. However, we cannot exclude that these costs, when used to simulate the expenditure in an Italian region, could have produced a certain level of overestimation. Second, we evaluated the preventability probability as a mean value among studies that performed economic assessments of ADEs. Other studies attempting an estimation of preventable ADEs with noneconomic purposes were not included in our review. We could not exclude that this could have affected our results in an unpredictable manner. However, in our simulation we assumed that 45% of ADEs could have been prevented. This probability is in line with that reported in an inpatient setting by a previous meta-analysis, ranging from 18.7 to 73.2% [48] . The extreme variability observed across studies may depend on the method used to assess preventability. Of note, our sensitivity analysis, where the preventability probability was calculated by inclusion of those studies using the most common method of estimation (i.e. Schumock and Thornton [34] ), confirmed the robustness of our results. Third, the choice of including studies reporting the mean ADE cost instead of the median cost could have biased the results towards an overestimation, since costs tend to be positively skewed. Fourth, although we included only studies published over the last 10 years, it is noteworthy that the observation period and the currency year adopted ranged from 1998 to 2011. This could have introduced some distortion, particularly when the currency year was assumed for studies in which information was missing [27] [28] [29] [30] 37] . Even with conversion into euros at a 30 December 2016 value in an attempt to make studies comparable, heterogeneity could persist. Fifth, relevant differences can be identified in the included studies in terms of sample size, ADE assessment methods [49] and items counted in the estimation of direct cost categories [50] . For instance, ICD coding is able to detect only a fraction of events, with a subsequent underestimation of ADEs. Furthermore, the sample size may have also influenced ADE detection. Indeed, small studies often use chart records, while the large ones usually adopt ICDcoded events. These differences may affect outcome precision across studies [49] . In addition, the Diagnosis-Related Group system is designed for reimbursement calculation, and therefore an underestimation of resource allocation could have been introduced for the evaluation of direct costs of ADEs [50] . Sixth, we searched only on MEDLINE and EMBASE. The use of other sources might have allowed identification of other relevant studies to be included, with significant effects on our results.
With regard to the extraction of ADEs from the Tuscan spontaneous reporting database, we firstly used reports from hospital physicians and specialists as a proxy of inpatient ADEs. Therefore, inpatient ADEs reported by other sources could have been misclassified, with a subsequent underestimation of the costs. Secondly, we did not discriminate between the costs of ADEs and the costs of ADRs since causality assessment of ADRs was not considered in our analysis. The application of these costs to spontaneous reports of suspected ADEs in the simulation represents an approximation for which the extent of the impact on the costs is not calculable.
Whatever the overall extent of these limitations, it is likely that underreporting of ADEs [51] had the largest influence on costs. Indeed, it is well-known that the ADEs spontaneously reported to the pharmacovigilance system represent only a small fraction of all ADEs occurring in the population. Therefore, if all ADEs occurring in the population could have been considered, it is reasonable that the actual cost of ADEs for the Tuscan healthcare system would be much higher than that reported in our results, as well as cost savings associated with their prevention also being higher.
Conclusions
Our simulation showed that ADEs could have a relevant economic impact on the Tuscan healthcare system. In this setting, the prevention of ADEs would result in important cost savings. These results could likely be extended to other healthcare systems. A reduction in the occurrence of preventable ADEs could be achieved through implementation of ADE evaluation systems; computer-assisted medication management systems with prescription alerts; continuing education of health professionals; and multidisciplinary support for the management of medical therapies. Further studies are warranted to test the net benefit achievable from the investments in these pharmacovigilance activities and the potential cost saving associated with the prevented ADEs.
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